GlassScriptPhysician profile
Garrick L Johnson
NPI 1891711156
$4,021.31
in general payments reported to CMS, 2019-2025
20 companies · $760 in 2025
The $760 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $162 · 2023: $1,192 · 2024: $1,795 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $720 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $720.00 |
| Education | $247.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $720.00 | 2024 | Onivyde |
| Janssen Biotech, INC. | $712.96 | 2021-2025 | Erleada, Carvykti, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $480.33 | 2023-2025 | Lynparza, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $378.09 | 2023-2024 | Pomalyst, Opdivo, Reblozyl |
| Daiichi Sankyo INC. | $280.54 | 2023-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $265.52 | 2022-2025 | Ninlaro, Iclusig |
| Novartis Pharmaceuticals Corporation | $203.80 | 2023-2025 | |
| Abbvie INC. | $189.86 | 2024-2025 | |
| Seagen INC. | $140.75 | 2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $137.19 | 2025 | |
| Pfizer INC. | $114.91 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $98.95 | 2024 | Libtayo |
| Astellas Pharma US INC | $98.95 | 2025 | Xtandi |
| Celgene Corporation | $73.78 | 2023-2025 | Reblozyl |
| Karyopharm Therapeutics INC. | $42.58 | 2024 | Xpovio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.91 | 2024 | |
| Glaxosmithkline, LLC. | $17.78 | 2025 | Ojjaara |
| Genentech USA, INC. | $17.19 | 2023 | Phesgo, Perjeta |
| Taiho Oncology, INC. | $14.79 | 2023 | |
| Novocure INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrick Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.